EMPLICITI

This brand name is authorized in Austria, Brazil, Estonia, Spain, Finland, Hong Kong, Ireland, Israel, Japan, Lithuania, Netherlands, Poland, United Kingdom, United States

Active ingredients

The drug EMPLICITI contains one active pharmaceutical ingredient (API):

1 Elotuzumab
UNII 1351PE5UGS - ELOTUZUMAB

Elotuzumab is an immunostimulatory humanised, IgG1 monoclonal antibody that specifically targets the SLAMF7 (signaling lymphocyte activation molecule family member 7) protein. Elotuzumab directly activates natural killer cells through both the SLAMF7 pathway and Fc receptors enhancing anti-myeloma activity in vitro. Elotuzumab also targets SLAMF7 on myeloma cells and through interactions with Fc receptors on specific immune cells, promotes the killing of myeloma cells through NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) and macrophage-mediated antibody-dependant cellular phagocytosis (ADCP).

Read about Elotuzumab

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
EMPLICITI Powder for concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L01FX08 Elotuzumab L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 505118040022902, 505118040023002
Country: EE Ravimiamet Identifier(s): 1718377, 1718388
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 1161088002
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 057220, 511556
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 328172, 328177
Country: HK Department of Health Drug Office Identifier(s): 64832, 64833
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 7814, 7815
Country: JP 医薬品医療機器総合機構 Identifier(s): 4291434D1020, 4291434D2027
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1080362, 1080363
Country: NL Z-Index G-Standaard, PRK Identifier(s): 136395, 136409
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100366092, 100366117
Country: US FDA, National Drug Code Identifier(s): 0003-2291, 0003-4522

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.